ArticleChild and adolescent psychiatry and mental health2026
The renaissance of research on psychedelics in child and adolescent psychopharmacology.
Article in Child and adolescent psychiatry and mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe recent regulatory approval of esketamine in adults heralded the renaissance of research into psychedelic compounds. However, the relevance of this resurgence for children and adolescents remains unclear. This review examines the rationale for investigating psychedelics in pediatric psychopharmacology.
methodsWe reviewed recent literature, regulatory documents, and clinical trial registries addressing the psychiatric use of classic serotonergic psychedelics (e.g., psilocybin, LSD), the entactogen MDMA, and dissociative compounds such as ketamine and esketamine in adolescent and young populations. Although ketamine is not a classic serotonergic psychedelic, it represents a paradigm for innovative pharmacological approaches.
resultsOngoing and planned trials primarily involve adolescents aged 16 years and older. Interest in these compounds is driven by significant unmet needs in child and adolescent psychiatry, where few medications are approved, and unsatisfactory therapeutic response is common. Potential targets include anorexia nervosa, core symptoms of autism spectrum disorders, obsessive-compulsive disorder, resistant depression, and severe PTSD. The fact that psychedelics may have long-lasting effects after only a few sessions raises the question of their effects on neuroplasticity.
conclusionsAlthough psychedelic research has entered a new phase in adult psychiatry, translation to pediatric populations requires caution due to developmental vulnerabilities and limited long-term safety data. Rigorous clinical trials, ethical safeguards, and regulatory oversight are essential before broader application in children and adolescents can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.